DURHAM, N.C. - Humacyte, Inc. (NASDAQ:HUMA), a clinical-stage biotech company, has launched an underwritten public offering of its common stock, the company disclosed Thursday. The firm, known for its bioengineered human tissue technology, also plans to offer underwriters a 30-day option to purchase up to an additional 15% of the shares sold in the offering.
Joint book-running managers for this offering include TD Cowen and Cantor, with BTIG as the lead manager. While the offering's completion is dependent on market conditions, and its size and terms remain uncertain, Humacyte aims to use the proceeds to advance its regenerative medicine pipeline.
The funds are also earmarked for supporting the FDA's review of its Biologics License Application for bioengineered human acellular vessels (HAVs), establishing commercial infrastructure for potential future product launches, and for general corporate purposes.
Humacyte's HAVs, currently in late-stage clinical trials, are designed for various vascular applications such as vascular trauma repair, arteriovenous access for hemodialysis, and peripheral artery disease.
Their innovative platform has garnered FDA's Regenerative Medicine Advanced Therapy designation for two of its HAV product candidates, emphasizing the company's role in advancing regenerative medical treatments.
The securities will be offered pursuant to an effective shelf registration statement filed with the Securities and Exchange Commission on September 1, 2022. Potential investors can access the preliminary prospectus supplement and accompanying prospectus on the SEC's website or obtain copies from the managing underwriters.
This press release does not constitute an offer to sell or a solicitation of an offer to buy any securities, and there will be no sale of these securities in any jurisdiction where such offer, solicitation, or sale would be unlawful before registration or qualification under the securities laws of any such jurisdiction.
The information in this article is based on a press release statement from Humacyte, Inc.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.